
### ü´Å Critical Care Medicine: Point-of-Care Ultrasonography in Undifferentiated Shock

#### ‚úÖ True Statements
1. In patients with **hypotension** in acute care settings, **point-of-care ultrasonography (POCUS)** has **good diagnostic accuracy** in determining the cause when physical examination findings are not helpful.
2. **Point-of-care ultrasonography (POCUS)** allows **immediate integration of diagnostic imaging data into clinical decision making** without the delay of traditional imaging studies.
3. **Hypovolemia**, **pneumothorax**, **right ventricular dysfunction**, **left ventricular dysfunction**, and **cardiac tamponade** can all be diagnosed with **point-of-care ultrasonography (POCUS)**.
4. In patients with **hypotension** and **probable undifferentiated shock**, **point-of-care ultrasonography (POCUS)** guides management decisions.

#### üí¨ Extra
1. Central venous catheter placement may be required for patients with shock but should not precede POCUS when peripheral access is adequate.
2. Computed tomography (CT) of the head is not the most appropriate next step in a patient with hypotension and undifferentiated shock without focal neurologic findings.
3. Vasopressors such as **norepinephrine** are reserved for patients in shock who remain hypotensive despite **intravenous fluid resuscitation**.

#### üè∑Ô∏è Tags
#CriticalCare #Shock #Hypotension #POCUS #Ultrasound #EmergencyMedicine

#### üìö Reference
D√≠az-G√≥mez JL, Mayo PH, Koenig SJ. Point-of-care ultrasonography. *N Engl J Med*. 2021;385(17):1593-602. PMID: 34670045 doi:10.1056/NEJMra1916062

#### üÜî Question ID
CCMCQ24033

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Critical Care Medicine ‚Äî Principles of Critical Care, Comprehensive Support of Critically Ill Patients, Comprehensive Support of Critically Ill Patients

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Comprehensive Support of Critically Ill Patients (Goals & Risks)
1. The goals of **intensive care unit (ICU)** care are to **restore health**, **allow discharge home**, and **minimize hospital time, complications, and long‚Äëterm effects** of critical illness.
2. When disease is **overwhelming or irreversible**, ICU goals may shift to **comfort‚Äëfocused end‚Äëof‚Äëlife care**.
3. ICU patients are at risk for **health care‚Äìassociated infections**, **pressure injuries**, **malnutrition**, **gastrointestinal bleeding**, **delirium**, and **weakness**.
4. **Protocolized care** in the ICU can **improve safety** and **reduce hospital‚Äëacquired conditions**.
5. **Stress ulcer prophylaxis** with **acid suppression** in at‚Äërisk patients **reduces clinically significant bleeding** but **does not reduce mortality**.
6. Practice guidelines give a **weak recommendation** to **stress ulcer prophylaxis** for at‚Äërisk patients with **coagulopathy**, **shock**, or **chronic liver disease**.
7. An **organ system‚Äìbased daily approach** helps teams review the main disease process, affected systems, and related interventions.
8. **Point‚Äëof‚Äëcare ultrasonography (POCUS)** in the ICU is useful for **hemodynamic instability**, **respiratory failure**, and **procedure guidance**.

#### ‚úÖ True Statements ‚Äî ICU Care Bundles
1. An **ICU care bundle** is a **set of interventions** that **improves outcomes** when used **together**.
2. **Care bundles** help clinicians **monitor patients** and **guide appropriate interventions**.

#### ‚úÖ True Statements ‚Äî High Value Care in the ICU
1. **Critical care** accounts for a **large proportion of U.S. health care costs**, with **similar survival and quality‚Äëof‚Äëlife outcomes** to other comparable countries.
2. **High value care** balances **clinical benefit** with **cost and harm** to improve patient outcomes.
3. ICU culture and high resource costs make it a prime setting to **avoid low‚Äëvalue care**.
4. **Choosing Wisely** initiatives promote **cost‚Äëeffective strategies** that **avoid waste and harm** in critical care.

#### ‚úÖ True Statements ‚Äî Sedation and Analgesia in the ICU
1. **Multimodal analgesia** is recommended in ICU care, with **opioids** as the **mainstay** and **preemptive analgesia** for **painful procedures**.
2. **Pain** should be **assessed at least every 4 hours** using an **objective scale**.
3. **Sedation** for mechanically ventilated patients should be **objectively monitored** (e.g., **Richmond Agitation‚ÄëSedation Scale**).
4. Guidelines favor **light sedation**, often with **analgesia‚Äëbased sedation** (intermittent opioids).
5. For **continuous sedation**, **propofol** or **dexmedetomidine** is preferred to **benzodiazepines**, which are linked to **increased delirium**.
6. For **light sedation**, **dexmedetomidine** may be associated with **less delirium** than **propofol**.
7. For **deep sedation** or patients at risk of **bradycardia**, **propofol** may be more appropriate.
8. **Correction of oversedation** should use **drug cessation** until appropriate level, then **restart at half** the prior dose.
9. **Cost and availability** should be considered when selecting sedative‚Äëanalgesic agents.

#### ‚úÖ True Statements ‚Äî Interruption of Sedation and Analgesia
1. **Daily spontaneous awakening trials** are associated with **shorter duration of mechanical ventilation**, **shorter ICU stay**, and **lower delirium incidence**, without a proven **90‚Äëday mortality** benefit.
2. **Protocolized light sedation** yields **similar outcomes** to **daily sedation interruption**.

#### ‚úÖ True Statements ‚Äî Delirium in the ICU
1. **Delirium** in the ICU is **common** and characterized by **disturbance in attention, awareness, and cognition**, with possible **hypo‚Äë or hyperactivity** and **emotional changes**.
2. ICU delirium is associated with **longer ICU stay**, **higher morbidity and mortality**, and **post‚ÄëICU cognitive impairment**.
3. Validated tools such as the **Confusion Assessment Method‚ÄëICU (CAM‚ÄëICU)** or **Intensive Care Delirium Screening Checklist** aid **early detection**.
4. **Neuroimaging** is **not routinely required** for ICU delirium evaluation.
5. Evidence **does not support medications** to **prevent or treat delirium**, **except** that **melatonin** may help **prevent** delirium.
6. **Antipsychotics** have **no conclusive benefit** and may cause **harm** in some patients.
7. **Benzodiazepines** should **not** be used for delirium **unless treating alcohol withdrawal or seizures**.
8. Management focuses on **identifying and correcting underlying causes** and using **multicomponent interventions** (e.g., **ABCDEF bundle**).
9. The **ABCDEF bundle** decreases **delirium duration**, **length of stay**, and **improves survival**, reducing **readmissions** and **costs**.
10. **Risk factors** for ICU delirium include **older age**, **pre‚Äëexisting dementia**, **previous coma**, **pre‚ÄëICU surgery or trauma**, **high illness severity on admission**, **benzodiazepine exposure**, and **blood transfusion**.

#### ‚úÖ True Statements ‚Äî Respiratory Support in the ICU (Definitions & Therapy)
1. ICU respiratory insufficiency includes **acute/acute‚Äëon‚Äëchronic hypoxemic respiratory failure**, **hypercapnic ventilatory failure**, and **upper airway impairment**.
2. **Hypoxemia** often results from **intrapulmonary shunting** due to **alveolar collapse or flooding**, but may also arise from **ventilation‚Äëperfusion mismatch** or **hypoventilation**.
3. **Therapies for hypoxemia** include treating the **underlying cause**, **increasing inspired oxygen fraction (FiO‚ÇÇ)**, and applying **positive end‚Äëexpiratory pressure (PEEP)**.
4. **Hypercapnic respiratory failure** arises from **dead space ventilation** or **alveolar hypoventilation** due to **weak respiratory muscles** or **increased elastic/resistive loads**.
5. **Mechanical ventilation** (invasive or noninvasive) is the **mainstay** for treating **hypercapnia**.
6. **Upper airway impairment** requires **airway maintenance** (e.g., obstruction or inability to protect the airway).

#### ‚úÖ True Statements ‚Äî Oxygen Therapy
1. Oxygen delivery is **titrated** to maintain appropriate **arterial oxygen saturation (SaO‚ÇÇ)** or **pulse oximetry (SpO‚ÇÇ)**; **higher saturation is not always desirable**.
2. Starting supplemental oxygen in **acute myocardial infarction or stroke** is **not recommended** when **SpO‚ÇÇ ‚â•93%**.
3. Guidelines recommend maintaining **SpO‚ÇÇ ‚â§96%** during oxygen therapy to **avoid hyperoxia**.
4. Higher **SaO‚ÇÇ** targets are beneficial in **carbon monoxide poisoning**, **cluster headache**, **pneumothorax**, **pregnancy**, and **vaso‚Äëocclusive events**.

#### ‚úÖ True Statements ‚Äî High‚ÄëFlow Nasal Cannula (HFNC)
1. **High‚Äëflow systems** mix and humidify gases to deliver **‚â•30 L/min** with a **consistent FiO‚ÇÇ** via cannula or mask; **true high flow** is usually **‚â•45 L/min**.
2. **High flow** provides some **positive airway pressure**, but the **pressure is flow‚Äëdependent** and **not quantifiable**.
3. In **acute hypoxemic respiratory failure**, **HFNC** may **reduce intubation** but **does not reduce mortality**.
4. In **COVID‚Äë19 cohorts**, **HFNC** reduced **intubation/mechanical ventilation rates** without **mortality benefit**.
5. **Guidelines recommend HFNC** in acute hypoxemic respiratory failure because **reduced intubation** is **important to patients**.
6. **Postextubation HFNC** may **lower recurrent respiratory failure and reintubation** versus conventional oxygen therapy.
7. In **high‚Äërisk postextubation** patients, **HFNC plus noninvasive ventilation** is **more effective** than **HFNC alone** in preventing **reintubation**.
8. The **ROX index** = (**SpO‚ÇÇ/FiO‚ÇÇ** expressed as %) / **respiratory rate** and helps **predict intubation risk** during **HFNC**.
9. **ROX ‚â•4.88 at 2, 6, and 12 hours** predicts **lower intubation risk**; **ROX <2.85 (2 h), <3.47 (6 h), or <3.85 (12 h)** predicts **HFNC failure**.
10. **Initial HFNC** should be started **in critical care** with **close monitoring** for **tolerance and effectiveness**.

#### ‚úÖ True Statements ‚Äî Mechanical Ventilatory Support: General Principles
1. **Noninvasive positive‚Äëpressure ventilation (PPV)** types include **continuous positive airway pressure (CPAP)** and **bilevel positive airway pressure (BPAP)**.
2. **CPAP** provides a **constant pressure** during **inspiration and expiration**.
3. **BPAP** provides **higher inspiratory pressure** than expiratory, **increasing tidal volume**.
4. **Average volume‚Äëassured pressure support (AVAPS)** integrates **volume‚Äë and pressure‚Äëcontrolled** features and may be **better tolerated** by some patients.
5. **Initiation** of any mechanical ventilatory support should occur in a **monitored unit**.
6. **Late application** of indicated noninvasive PPV is associated with **higher intubation rates** and **worse outcomes**.
7. **Excessive tidal volumes** during noninvasive PPV can **cause harm**.
8. **Complications** of noninvasive PPV include **mucosal dryness**, **nasal congestion**, **facial erosions**, **gastric insufflation**, and **rare pulmonary barotrauma**.

#### ‚úÖ True Statements ‚Äî Noninvasive Mechanical Ventilation: Indications & Contraindications
1. Evidence supports noninvasive PPV for **acute COPD exacerbation**, **cardiogenic pulmonary edema**, **neuromuscular disease**, and **obesity hypoventilation syndrome**.
2. Noninvasive PPV is indicated **postextubation** for patients **at high risk for reintubation** (e.g., **age >65 years**, **heart failure**, **COPD**).
3. **Contraindications** to noninvasive PPV include **persistent altered mental status**, **inability to protect the airway**, **emesis**, **increased secretions**, **gastric distention**, **airway obstruction**, **recent esophageal surgery**, **cardiac arrest**, **facial trauma/surgery**, **mask intolerance**, **anticipated long‚Äëterm ventilatory need**, and **impaired respiratory drive**.

#### ‚úÖ True Statements ‚Äî Application & Monitoring of Noninvasive PPV
1. **Proper mask sizing** and **patient coaching** are essential for tolerance.
2. After initiation, monitor **comfort**, **skin integrity**, **gastric distention**, and **eye irritation**.
3. Assess **tidal volumes**, **respiratory rate**, **blood pH**, **oxygen saturation**, and **mental status** for **effectiveness** and **clinical improvement**.

#### ‚úÖ True Statements ‚Äî Invasive Mechanical Ventilation
1. Indications include **hypoxemic** or **hypercapnic respiratory failure** with **contraindications to noninvasive PPV** or **inability to protect the airway**.
2. Ventilator strategy should focus on **lung‚Äëprotective ventilation** using the **lowest effective tidal volume and plateau pressure** to avoid **volutrauma** and **atelectrauma**.
3. When risk of lung injury decreases and patients are awake, prioritize **patient‚Äëventilator synchrony** and **comfort** (e.g., **pressure support** or **synchronized intermittent mandatory ventilation**).

#### ‚úÖ True Statements ‚Äî Weaning off Mechanical Ventilation
1. Patients should be **liberated from ventilation** as soon as feasible.
2. Perform **daily spontaneous breathing trials (SBTs)** for **‚â•30 minutes and ‚â§2 hours** using **low pressure support (‚â§8 cm H‚ÇÇO)** or a **T‚Äëpiece**.
3. Combining **SBTs** with **daily awakening trials** or **light sedation protocols** **reduces ventilation time**, **ICU/hospital length of stay**, and **mortality**.

#### ‚úÖ True Statements ‚Äî Hemodynamic Support in the ICU
1. **Invasive hemodynamic monitoring** (e.g., **arterial lines**, **pulmonary artery catheters**) should be used **only when noninvasive data are insufficient** and **removed early** to limit **infection/thrombosis**.
2. The **mean arterial pressure (MAP) threshold of 60‚Äì65 mm Hg** is generally adequate for **organ perfusion** in most adults.
3. **Hypotension** does **not always equate** to **impaired tissue perfusion**.
4. **Serum lactate** reflects **tissue dysfunction** but is **not a direct measure** of **tissue hypoxia** and must be interpreted **in context**.
5. Management should **target the cause** (e.g., **preload‚Äërelated hypotension** ‚Üí **volume resuscitation**).

#### ‚úÖ True Statements ‚Äî Intravenous Access in the ICU
1. **Short peripheral intravenous catheters** suffice for **most medications**, **fluids**, and **blood products**, and are **preferred for rapid resuscitation**.
2. **Central venous access** is indicated for **vesicant vasoactive infusions**, **hemodynamic monitoring**, or **extracorporeal therapies** when peripheral access is **inadequate**.
3. **Ultrasound guidance** reduces **procedure complications** (e.g., **arterial injury**, **nerve injury**, **bleeding**, **pneumothorax**).
4. All intravenous devices should be **removed as soon as possible** to **reduce infection and thrombosis**.

#### ‚úÖ True Statements ‚Äî Intravenous Fluids and Volume Expanders
1. **Intravenous fluids** should be **prescribed deliberately** due to potential **adverse effects**.
2. **Crystalloids** contain **water with electrolytes**; **colloids** contain **larger particles** such as **starches or proteins**.
3. **Balanced solutions** with **lower chloride** (e.g., **lactated Ringer**) are generally **preferred** over **0.9% saline** because they **minimize metabolic acidosis** and electrolyte disturbances.
4. Fluid **composition, dose, and duration** should be tailored to **resuscitation**, **replacement**, or **maintenance goals**.

#### ‚úÖ True Statements ‚Äî Blood Pressure Support in the ICU
1. **Shock** reflects **sustained tissue hypoperfusion** causing **cellular dysfunction** and **death**.
2. **Assessment of perfusion** includes **skin findings**, **capillary refill**, **jugular venous distention**, **vital signs**, and **focused cardiac evaluation**.
3. **Norepinephrine** is the **most used vasopressor** and may **reduce mortality** in some populations, with **other agents** appropriate in **specific scenarios**.

#### ‚úÖ True Statements ‚Äî Nutritional Support in the ICU
1. **Malnutrition** increases **morbidity and mortality** in critical illness; **all ICU patients** require **nutritional evaluation**.
2. **Enteral nutrition** is **preferred**, with **early initiation (within 24‚Äì48 hours)** associated with **lower mortality** and **fewer infections**.
3. Use **gastric or postpyloric tubes** when patients **cannot maintain volitional intake**; **postpyloric feeding** is recommended when **aspiration risk is high**, but **placement delays** should **not delay enteral nutrition**.
4. **Routine gastric residual measurement** is **not recommended**, as it **delays feeding goals**, **clogs access**, and may **increase aspiration risk**.
5. In patients receiving enteral nutrition, **supplemental parenteral nutrition** should be considered **only after 7‚Äì10 days** if **<60%** of **energy/protein** needs are met enterally.
6. If **enteral feeding is not possible** and the patient was **adequately nourished**, consider **parenteral nutrition after 7‚Äì10 days**.
7. If the patient is **severely malnourished or at high risk** and **enteral feeding is not possible**, **start parenteral nutrition as soon as possible**.

#### ‚úÖ True Statements ‚Äî Early Mobilization in the ICU
1. **Immobility** contributes to **weakness**, **pressure ulcers**, **osteoporosis**, **gastrointestinal dysmotility**, and **dysautonomia** in critical illness.
2. Even **a few days** of immobility can cause **prolonged weakness**, with **deficits persisting at 1 and 5 years**.
3. **Early mobilization** strategies‚Äîincluding **sedation interruption** and **early physical/occupational therapy**‚Äîare associated with **shorter ICU/hospital stays**, **fewer ventilation days**, and **better quality of life and function**.

#### ‚úÖ True Statements ‚Äî Palliative Care in the ICU: Withdrawal of Life‚ÄëSustaining Therapy
1. After the decision to **discontinue life‚Äësustaining therapy** consistent with **goals of care**, focus shifts to **symptom‚Äëdirected care**.
2. **Analgesia**, **appropriate sedation**, and other **comfort measures** should be provided as needed.
3. **Paralytics**, **vasopressors**, and **inotropes** may be **discontinued stepwise**, followed by **mechanical ventilation** and **artificial airway** as appropriate.
4. **Opioids** treat **pain and dyspnea**; **benzodiazepines** are **preferred** for **additional sedation**; **propofol** or **barbiturates** may also be considered.
5. **Compassionate communication** throughout the ICU stay helps **clarify goals** and involves **family** in **symptom assessment**.

#### üè∑Ô∏è Tags
#CriticalCare #ICU #Sedation #Delirium #MechanicalVentilation #HFNC #OxygenTherapy #Hemodynamics #Vasopressors #EnteralNutrition #EarlyMobilization #PalliativeCare #HighValueCare #CareBundles

---

#### üóæ Supplemental Tables

<!-- ICU Care Bundles -->
<table>
  <caption><strong>ICU Care Bundles</strong></caption>
  <thead>
    <tr><th colspan="2">Ventilator-Associated Pneumonia<sup>a</sup></th></tr>
  </thead>
  <tbody>
    <tr><td>Head of bed elevated at least 30 degrees</td></tr>
    <tr><td>Daily sedation interruption and assessment of readiness to extubate (daily spontaneous awakening trials and spontaneous breathing trials)</td></tr>
    <tr><td>Endotracheal tubes with subglottic suction</td></tr>
    <tr><td>Early exercise or mobilization for physical conditioning</td></tr>
    <tr><td>Daily toothbrushing without chlorhexidine</td></tr>
    <tr><td>Early enteral vs. parenteral nutrition</td></tr>
    <tr><td>Ventilator circuits changed only if malfunctioning or visibly soiled</td></tr>
  </tbody>
  <thead>
    <tr><th>Central Line‚ÄìAssociated Bloodstream Infections<sup>b</sup></th></tr>
  </thead>
  <tbody>
    <tr><td>Hand hygiene</td></tr>
    <tr><td>Maximal barrier precautions</td></tr>
    <tr><td>Chlorhexidine skin antisepsis</td></tr>
    <tr><td>Avoidance of femoral access</td></tr>
    <tr><td>Daily review of line necessity and removal of unnecessary lines</td></tr>
  </tbody>
  <thead>
    <tr><th>Sepsis<sup>c</sup></th></tr>
  </thead>
  <tbody>
    <tr><td><strong>Sepsis standard operating procedures (1‚Äëhour bundle):</strong></td></tr>
    <tr><td>Measure lactate level</td></tr>
    <tr><td>Obtain blood cultures before antibiotics</td></tr>
    <tr><td>Administer broad‚Äëspectrum antibiotics</td></tr>
    <tr><td>Administer 30 mL/kg crystalloids for hypotension or lactate ‚â•4 mEq/L (4 mmol/L) (or document reasoning not to administer fluid)</td></tr>
    <tr><td>Use vasopressors if no response to fluids; keep MAP &gt;65 mm Hg</td></tr>
  </tbody>
</table>
<p><em>MAP = mean arterial blood pressure, calculated as [(2 √ó diastolic) + systolic]/3.</em></p>
<p><em><sup>a</sup> Recommendations based on Klompas M, Branson R, Cawcutt K, et&nbsp;al. Strategies to prevent ventilator‚Äëassociated events, and nonventilator hospital‚Äëacquired pneumonia in acute‚Äëcare hospitals: 2022 update. <em>Infect Control Hosp Epidemiol.</em> 2022;43:687‚Äë713. PMID: 35589091 doi:10.1017/ice.2022.88</em></p>
<p><em><sup>b</sup> Recommendations from the Institute for Healthcare Improvement.</em></p>
<p><em><sup>c</sup> Recommendations based on Evans L, Rhodes A, Alhazzani W, et&nbsp;al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <em>Crit Care Med.</em> 2021;49:e1063‚Äë143. PMID: 34605781 doi:10.1097/CCM.0000000000005337</em></p>

#### ‚úÖ True Statements (from Table: ICU Care Bundles)
1. The **ventilator‚Äëassociated pneumonia bundle** includes **head‚Äëof‚Äëbed elevation ‚â•30¬∞**, **daily sedation interruption with readiness‚Äëto‚Äëextubate assessment**, use of **subglottic suction endotracheal tubes**, **early mobilization**, **daily toothbrushing without chlorhexidine**, **early enteral nutrition**, and **changing ventilator circuits only if malfunctioning or soiled**.
2. The **central line‚Äìassociated bloodstream infection bundle** includes **hand hygiene**, **maximal barrier precautions**, **chlorhexidine skin antisepsis**, **avoiding femoral access**, and **daily review/removal of unnecessary lines**.
3. The **1‚Äëhour sepsis bundle** includes **lactate measurement**, **blood cultures before antibiotics**, **broad‚Äëspectrum antibiotics**, **30 mL/kg crystalloid for hypotension or lactate ‚â•4 mEq/L**, and **vasopressors to maintain MAP &gt;65 mm Hg when fluids are insufficient**.

---

<!-- Society of Critical Care Medicine Choosing Wisely Recommendations -->
<table>
  <caption><strong>Society of Critical Care Medicine Choosing Wisely Recommendations</strong></caption>
  <thead><tr><th>#</th><th>Recommendation</th></tr></thead>
  <tbody>
    <tr><td>1</td><td>Don't order diagnostic tests at regular intervals (such as every day); order in response to specific clinical questions.</td></tr>
    <tr><td>2</td><td>Don't transfuse erythrocytes in hemodynamically stable, non‚Äëbleeding ICU patients with hemoglobin &gt;7 g/dL (70 g/L).</td></tr>
    <tr><td>3</td><td>Don't delay providing nutrition‚Äîprefer **enteral** over **parenteral**‚Äîto critically ill patients during the first 24‚Äì36 hours of critical illness.</td></tr>
    <tr><td>4</td><td>Don't deeply sedate mechanically ventilated patients without a specific indication and without daily attempts to lighten sedation.</td></tr>
    <tr><td>5</td><td>Don't continue life support for patients at high risk for death or severely impaired recovery without offering the alternative of **comfort‚Äëfocused care**.</td></tr>
    <tr><td>6</td><td>Don't leave lines, tubes, or drains in ICU patients that have not been evaluated at least once daily and judged to provide continued benefit.</td></tr>
    <tr><td>7</td><td>Don't delay mechanical ventilator weaning unless there is **clinical evidence of need**.</td></tr>
    <tr><td>8</td><td>Don't delay discontinuation of antibiotics in culture‚Äënegative, asymptomatic patients with sterile cultures beyond **48 hours**.</td></tr>
    <tr><td>9</td><td>Don't delay mobilizing patients beyond **48 hours** from ICU admission when patients pass mobilization safety screening.</td></tr>
    <tr><td>10</td><td>Don't provide care that does not align with **documented patient and family goals, values, and preferences**.</td></tr>
  </tbody>
</table>
<p><em>Recommendations from Halpern SD, Becker D, Curtis JR, et&nbsp;al; Choosing Wisely Taskforce. Am J Respir Crit Care Med. 2014;190:818‚Äë26. PMID: 25271745 doi:10.1164/rccm.201407‚Äë1317ST and Zimmerman JJ, Harmon LA, Smithburger PL, et&nbsp;al. <em>Crit Care Med.</em> 2021;49:472‚Äë81. PMID: 33555779 doi:10.1097/CCM.0000000000004876</em></p>

#### ‚úÖ True Statements (from Table: Society of Critical Care Medicine Choosing Wisely Recommendations)
1. **Routine daily testing** should be **avoided** in the ICU; testing should target **specific clinical questions**.
2. **Restrictive transfusion** is recommended for **stable, non‚Äëbleeding ICU patients** with hemoglobin **&gt;7 g/dL**.
3. **Early enteral nutrition** within **24‚Äì36 hours** is preferred over parenteral nutrition in the **critically ill**.
4. **Deep sedation** without indication and without **daily lightening attempts** should be **avoided**.
5. Offer **comfort‚Äëfocused care** as an alternative to ongoing life support for patients with **poor prognosis**.
6. **Indwelling devices** should be **reassessed daily** and **removed** if no longer beneficial.
7. **Ventilator weaning** should **not be delayed** without clinical need.
8. **Antibiotics** should be **stopped by 48 hours** if cultures are sterile and the patient is **asymptomatic**.
9. **Early mobilization** (within **48 hours**) is recommended after passing safety screening.
10. Care should align with **documented patient and family goals**.

---

<!-- Summary of Analgesia and Sedation Recommendations for Critical Care Patients -->
<table>
  <caption><strong>Summary of Analgesia and Sedation Recommendations for Critical Care Patients</strong></caption>
  <thead><tr><th>Section</th><th>Recommendations</th></tr></thead>
  <tbody>
    <tr>
      <td><strong>Analgesia ‚Äî Nonpharmacologic</strong></td>
      <td>
        Music therapy; local cold therapy for procedures; massage therapy; daily sedation interruption; relaxation therapy; family involvement
      </td>
    </tr>
    <tr>
      <td><strong>Analgesia ‚Äî Pharmacologic</strong></td>
      <td>
        Opioids remain the mainstay (analgesia‚Äëbased sedation); multimodal therapy (nonpharmacologic and nonopioid); consider opioid reduction strategies (adjunct acetaminophen; adjunct low‚Äëdose ketamine for postsurgical patients; adjunct gabapentin, carbamazepine, or pregabalin for nonneuropathic pain); preprocedural pain management with opioid or NSAID
      </td>
    </tr>
    <tr>
      <td><strong>Sedation</strong></td>
      <td>
        Use <em>light sedation</em> rather than deep sedation in mechanically ventilated patients; use sedation protocols (nurse‚Äëdriven or daily sedation interruption); favor propofol or dexmedetomidine over benzodiazepines (dexmedetomidine may be preferred over propofol for light sedation); use an objective scale to titrate sedation; use a bispectral index when scales cannot be used (e.g., neuromuscular blockade)
      </td>
    </tr>
  </tbody>
</table>
<p><em>Data from Devlin JW, Skrobik Y, G√©linas C, et&nbsp;al. <em>Crit Care Med.</em> 2018;46:e825‚Äë73. PMID: 30113379 and Lewis K, Balas MC, Stollings JL, et&nbsp;al. <em>Crit Care Med.</em> 2025;53:e711‚Äë27. PMID: 39982143.</em></p>

#### ‚úÖ True Statements (from Table: Summary of Analgesia and Sedation Recommendations)
1. **Opioids** are the **mainstay of analgesia** in the ICU within a **multimodal** strategy; **preprocedural analgesia** is recommended.
2. **Light sedation** is preferred over deep sedation for **mechanically ventilated** patients and should follow **protocols**.
3. **Propofol** or **dexmedetomidine** is **preferred** to **benzodiazepines** for sedation; **objective scales** (and **bispectral index** when needed) guide titration.

---

<!-- Causes, Features, and Management of Delirium -->
<table>
  <caption><strong>Causes, Features, and Management of Delirium</strong></caption>
  <thead>
    <tr>
      <th>Predisposing Factors</th>
      <th>Provoking Factors</th>
      <th>Clinical Features of Delirium</th>
      <th>Management of Delirium</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>History of delirium; advanced age (‚â•70 y); vision or hearing impairment; preexisting cognitive impairment; poor nutritional status; poor functional status; multiple comorbidities; kidney disease; alcohol use disorder; depression; polypharmacy</td>
      <td>Poorly controlled pain; deliriogenic medications (e.g., benzodiazepines, anticholinergics, opioids)<sup>a</sup>; sleep‚Äëwake disruption/sleep deprivation; constipation; dehydration; urinary retention; severe illness; infection; hypoxia; surgical stress; urinary catheter and other tethers; sensory deprivation (e.g., no hearing aids or glasses)</td>
      <td>Fluctuations in mentation; hyperactive or hypoactive states; disorganized thoughts; delusions; hallucinations; poorly sustained attention; altered circadian rhythm; tremors (with occasional myoclonus); hyperreflexia; restlessness or somnolence; amnesia; increased sympathetic tone (notably with alcohol withdrawal)</td>
      <td>Engage and empower family; allow sunlight/open windows; redirect with calm tones; assess, prevent, and manage pain; promote early mobility/exercise; avoid restraints when possible (use sedation/analgesia only for severe agitation); repeat neurologic examinations; maintain oxygen saturation &gt;92%; in ICU, perform SAT and SBT</td>
    </tr>
  </tbody>
</table>
<p><em>SAT = spontaneous awakening trial; SBT = spontaneous breathing trial.</em></p>
<p><em><sup>a</sup> See American Geriatrics Society Beers criteria for potentially inappropriate medication use in older adults.</em></p>

#### ‚úÖ True Statements (from Table: Causes, Features, and Management of Delirium)
1. **Predisposing factors** for ICU delirium include **advanced age**, **sensory impairment**, **cognitive impairment**, **poor nutrition/functional status**, **multiple comorbidities**, **kidney disease**, **alcohol use disorder**, **depression**, and **polypharmacy**.
2. **Provoking factors** include **deliriogenic medications**, **sleep disruption**, **constipation/dehydration/urinary retention**, **severe illness/infection/hypoxia**, **surgical stress**, and **sensory deprivation**.
3. **Clinical features** include **fluctuating attention and awareness**, **hyperactive or hypoactive states**, **psychotic features**, and **autonomic signs**.
4. **Management** emphasizes **nonpharmacologic measures**, **early mobility**, **pain control**, **oxygenation &gt;92%**, and use of **SAT/SBT** in the ICU.

---

<!-- ABCDEF Care Bundle for Managing ICU Delirium -->
<table>
  <caption><strong>ABCDEF Care Bundle for Managing ICU Delirium</strong></caption>
  <thead><tr><th>Letter</th><th>Action</th></tr></thead>
  <tbody>
    <tr><td>A</td><td><strong>Assess</strong>, prevent, and manage pain</td></tr>
    <tr><td>B</td><td>Perform <strong>Both</strong> SAT and SBT</td></tr>
    <tr><td>C</td><td><strong>Choice</strong> of sedation and analgesia</td></tr>
    <tr><td>D</td><td><strong>Delirium</strong>: assessment, prevention, and management</td></tr>
    <tr><td>E</td><td><strong>Early</strong> mobility and exercise</td></tr>
    <tr><td>F</td><td><strong>Family</strong> engagement and empowerment</td></tr>
  </tbody>
</table>
<p><em>SAT = spontaneous awakening trial; SBT = spontaneous breathing trial.</em></p>
<p><em>Recommendations from Devlin JW, Skrobik Y, G√©linas C, et&nbsp;al. <em>Crit Care Med.</em> 2018;46:e825‚Äë73. PMID: 30113379 doi:10.1097/CCM.0000000000003299</em></p>

#### ‚úÖ True Statements (from Table: ABCDEF Care Bundle for Managing ICU Delirium)
1. The **ABCDEF bundle** includes **pain assessment/management**, **SAT and SBT**, **sedation/analgesia choice**, **delirium prevention/management**, **early mobility**, and **family engagement**.

---

<!-- Modes of Noninvasive Positive-Pressure Ventilation -->
<table>
  <caption><strong>Modes of Noninvasive Positive‚ÄëPressure Ventilation</strong></caption>
  <thead>
    <tr>
      <th>Mode</th><th>Function</th><th>Physiologic Effects</th><th>Indications</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CPAP</td>
      <td>Applies and maintains a constant airway pressure throughout the respiratory cycle</td>
      <td>Maintains patent airway in obstructive sleep apnea; increases functional residual capacity; increases mean airway pressure</td>
      <td>Obstructive sleep apnea; pulmonary edema; excessive dynamic airway collapse; postextubation in high‚Äërisk patients to prevent respiratory failure</td>
    </tr>
    <tr>
      <td>BPAP</td>
      <td>Applies two different levels of airway pressure: IPAP and EPAP</td>
      <td>As with CPAP but also decreases work of breathing and augments tidal volume</td>
      <td>COPD exacerbation; obesity hypoventilation syndrome; neuromuscular diseases; postextubation in high‚Äërisk patients; time‚Äëlimited trial in selected ‚Äúdo not intubate‚Äù patients with clear goals</td>
    </tr>
    <tr>
      <td>BPAP with S/T mode</td>
      <td>BPAP with a minimum set respiration rate</td>
      <td>In central apnea, continues to deliver breaths</td>
      <td>Hypoventilation; central apneas</td>
    </tr>
    <tr>
      <td>AVAPS</td>
      <td>Maximum and minimum IPAP with a target tidal volume</td>
      <td>Ensures delivery of preset tidal volume to maintain adequate minute ventilation</td>
      <td>Hypoventilation; central apneas; COPD exacerbation</td>
    </tr>
  </tbody>
</table>
<p><em>AVAPS = average volume‚Äëassured pressure support; BPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; EPAP = expiratory positive airway pressure; IPAP = inspiratory positive airway pressure; S/T = spontaneous/timed.</em></p>
<p><em>Data from Rochwerg B, Brochard L, Elliott MW, et&nbsp;al. <em>Eur Respir J.</em> 2017;50. PMID: 28860265 doi:10.1183/13993003.02426‚Äë2016</em></p>

#### ‚úÖ True Statements (from Table: Modes of Noninvasive Positive‚ÄëPressure Ventilation)
1. **CPAP** delivers **constant airway pressure** and increases **functional residual capacity**; indications include **OSA** and **pulmonary edema**.
2. **BPAP** provides **higher inspiratory** than expiratory pressure, **reducing work of breathing** and **increasing tidal volume**; indications include **COPD exacerbation** and **obesity hypoventilation syndrome**.
3. **S/T mode** ensures a **minimum respiratory rate** for **central apnea**.
4. **AVAPS** targets a **preset tidal volume** to maintain **minute ventilation**.

---

<!-- Most Frequently Used Ventilator Modes -->
<table>
  <caption><strong>Most Frequently Used Ventilator Modes</strong></caption>
  <thead>
    <tr>
      <th>Common Name</th>
      <th>Mode Classification</th>
      <th>Breath Control Variable</th>
      <th>Breath Sequence</th>
      <th>Targeting Scheme</th>
      <th>Characteristics</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Volume control assist/control</td>
      <td>VC‚ÄëCMVs (set‚Äëpoint targeting)</td>
      <td>VC: Ventilator controls flow (volume) during mandatory breath; if effort/compliance/resistance change, set tidal volume is delivered (inspiratory pressure will change)</td>
      <td>CMV: All breaths are mandatory; patient may or may not trigger the breath; ventilator always cycles the breath when set tidal volume delivered</td>
      <td>Set‚Äëpoints: operator sets all breath parameters (flow waveform, flow rate, volume); ventilator does not adjust to patient effort or lung changes</td>
      <td>Ensures minimum minute ventilation; allows low tidal volume; least comfortable due to flow limitation; serves safety goal for ARDS (e.g., 6 cc/kg)</td>
    </tr>
    <tr>
      <td>Pressure control assist/control</td>
      <td>PC‚ÄëCMVs (set‚Äëpoint targeting)</td>
      <td>PC: Ventilator controls inspiratory pressure during mandatory breath; if effort/compliance/resistance change, delivered tidal volume will change</td>
      <td>CMV: All breaths are mandatory; patient may or may not trigger; ventilator cycles when preset inspiratory time elapses</td>
      <td>Set‚Äëpoints: operator sets inspiratory pressure and time; ventilator does not adapt to patient effort or lung changes</td>
      <td>Ensures pressure does not rise above a set limit; tidal volume depends on effort/compliance/resistance; serves safety if tidal volume within range</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Most Frequently Used Ventilator Modes)
1. **Volume‚Äëcontrol assist/control (VC‚ÄëCMV)** delivers a **set tidal volume** each mandatory breath, ensuring **minimum minute ventilation** and supporting **low tidal volume** strategies for **ARDS**.
2. **Pressure‚Äëcontrol assist/control (PC‚ÄëCMV)** delivers a **set inspiratory pressure** with **tidal volume varying** by patient effort and lung mechanics, preventing pressures above a **set limit**.

---

<!-- Common Criteria for Spontaneous Breathing Trials and Extubation -->
<table>
  <caption><strong>Common Criteria for Spontaneous Breathing Trials and Extubation<sup>a</sup></strong></caption>
  <thead><tr><th>Section</th><th>Criteria</th></tr></thead>
  <tbody>
    <tr>
      <td><strong>Criteria to Perform SBT</strong></td>
      <td>Cause of respiratory failure improved; FiO‚ÇÇ ‚â§50% and PEEP ‚â§5‚Äì8 cm H‚ÇÇO; pH &gt;7.25; hemodynamic stability; ability to breathe spontaneously</td>
    </tr>
    <tr>
      <td><strong>Criteria to Pass SBT ‚Äî at least 30 minutes without:</strong></td>
      <td>Clinical evidence of respiratory distress (SpO‚ÇÇ &lt;90% or RR &gt;35/min); new arrhythmias; tachycardia; hypotension or hypertension</td>
    </tr>
    <tr>
      <td><strong>Additional Considerations Before Extubation</strong></td>
      <td>Quantity of secretions/need for suctioning; adequacy of cough; altered mental status</td>
    </tr>
  </tbody>
</table>
<p><em>PEEP = positive end‚Äëexpiratory pressure; SBT = spontaneous breathing trial.</em></p>
<p><em><sup>a</sup> These criteria may differ among institutions.</em></p>

#### ‚úÖ True Statements (from Table: Common Criteria for SBT and Extubation)
1. **SBT performance criteria** include **FiO‚ÇÇ ‚â§50%**, **PEEP ‚â§5‚Äì8 cm H‚ÇÇO**, **pH &gt;7.25**, **hemodynamic stability**, and **spontaneous breathing**.
2. **SBT passing criteria** require **‚â•30 minutes** without **respiratory distress**, **SpO‚ÇÇ &lt;90%**, **RR &gt;35/min**, **new arrhythmias**, **tachycardia**, or **blood pressure instability**.
3. **Before extubation**, assess **secretions**, **cough adequacy**, and **mental status**.

---

<!-- Types of Venous Access -->
<table>
  <caption><strong>Types of Venous Access</strong></caption>
  <thead>
    <tr>
      <th>Type</th><th>Indications</th><th>Duration</th><th>Potential Complications</th><th>Contraindications</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Peripheral IV</td>
      <td>IV fluids, medications, blood products</td>
      <td>A few days</td>
      <td>Thrombophlebitis, bruising, hematoma; low bloodstream infection risk; rarely nerve/arterial injury</td>
      <td>Relative: current or planned dialysis; presence of AV fistula; infected/burnt skin at insertion; DVT‚Äëaffected limb</td>
    </tr>
    <tr>
      <td>Peripherally inserted central venous catheter (PICC)</td>
      <td>Delivery of potentially caustic medications (vasoactive agents, sedatives, antibiotics); central venous access</td>
      <td>A few days to 1 year</td>
      <td>Low pneumothorax risk; reduced infection risk vs nontunneled central catheter; risk of clot formation/occlusion (smaller vessel diameter)</td>
      <td>As above</td>
    </tr>
    <tr>
      <td>Temporary nontunneled central venous access</td>
      <td>Same as PICC; short‚Äëterm dialysis; central venous pressure monitoring</td>
      <td>Infection risk increased after 7 days</td>
      <td>Infection; site‚Äëspecific complications (e.g., pneumothorax for subclavian or low internal jugular approach)</td>
      <td>As above</td>
    </tr>
    <tr>
      <td>Long‚Äëterm tunneled</td>
      <td>Long‚Äëterm TPN, chemotherapy, long‚Äëterm antibiotics, dialysis; cuff allows tissue adherence to reduce infection/dislodgement</td>
      <td>&gt;6 weeks</td>
      <td>Infection; risks similar to nontunneled catheter during placement (e.g., pneumothorax)</td>
      <td>As above</td>
    </tr>
    <tr>
      <td>Ports or totally implanted devices</td>
      <td>Long‚Äëterm intermittent access (e.g., chemotherapy)</td>
      <td>&gt;6 weeks</td>
      <td>Lowest infection risk; more difficult to implant; higher cost; hidden extravasation beneath skin</td>
      <td>As above</td>
    </tr>
    <tr>
      <td>Intraosseous (tibia or humeral head)</td>
      <td>When IV access is not otherwise attainable in emergent setting [adults]</td>
      <td>About 24 hours</td>
      <td>Low infection risk; slower flow; if infusion pain, use 2% preservative‚Äëfree lidocaine slowly</td>
      <td>Do not place in a **fractured bone**, in **osteoporosis**, or after a **recent (24‚Äì48 h) intraosseous attempt**</td>
    </tr>
  </tbody>
</table>
<p><em>AV = arteriovenous; DVT = deep venous thrombosis; IV = intravenous; TPN = total parenteral nutrition.</em></p>

#### ‚úÖ True Statements (from Table: Types of Venous Access)
1. **Peripheral IVs** are suitable for **fluids/medications/blood products** for **a few days**, with **low infection risk**.
2. **PICCs** allow **central access** for **caustic infusions** and may be used up to **1 year**, but carry **thrombosis/occlusion** risk.
3. **Nontunneled central lines** have **higher infection risk after 7 days** and **site‚Äëspecific complications**.
4. **Tunneled lines** and **ports** support **long‚Äëterm access (&gt;6 weeks)** with **lower infection** for ports but **greater implantation complexity/cost**.
5. **Intraosseous access** is an **emergency option** for ~**24 hours** and is **contraindicated** in **fracture**, **osteoporosis**, or **recent IO attempt**.

---

<!-- Commonly Used Intravenous Fluids -->
<table>
  <caption><strong>Commonly Used Intravenous Fluids</strong></caption>
  <thead><tr><th>Formulation</th><th>Solution Type</th><th>Fluid Composition</th></tr></thead>
  <tbody>
    <tr>
      <td>0.9% saline</td>
      <td>Crystalloid (Unbalanced)</td>
      <td>Sodium 154 mEq/L; Chloride 154 mEq/L; Osmolarity 308 mOsm/L</td>
    </tr>
    <tr>
      <td>Lactated Ringer</td>
      <td>Crystalloid (Balanced)</td>
      <td>Calcium 3 mEq/L; Sodium 130 mEq/L; Potassium 4 mEq/L; Chloride 109 mEq/L; Lactate 28 mEq/L; Osmolarity 273 mOsm/L</td>
    </tr>
    <tr>
      <td>Plasma‚ÄëLyte</td>
      <td>Crystalloid (Balanced)</td>
      <td>Sodium 140 mEq/L; Potassium 5 mEq/L; Chloride 98 mEq/L; Magnesium 3 mEq/L; Acetate 27 mEq/L; Gluconate 23 mEq/L</td>
    </tr>
    <tr>
      <td>Hartmann</td>
      <td>Crystalloid (Balanced)</td>
      <td>Calcium 4 mEq/L; Sodium 131 mEq/L; Potassium 5 mEq/L; Chloride 111 mEq/L; Lactate 29 mEq/L; Magnesium 3 mEq/L; Osmolarity 279 mOsm/L</td>
    </tr>
    <tr>
      <td>Albumin</td>
      <td>Colloid</td>
      <td>Iso‚Äëoncotic (5%); Hyper‚Äëoncotic (20% and 25%)</td>
    </tr>
  </tbody>
</table>
<p><em>Data from Malbrain MLNG, Langer T, Annane D, et&nbsp;al. <em>Ann Intensive Care.</em> 2020;10:64. PMID: 32449147 doi:10.1186/s13613‚Äë020‚Äë00679‚Äë3</em></p>

#### ‚úÖ True Statements (from Table: Commonly Used Intravenous Fluids)
1. **Balanced crystalloids** (e.g., **Lactated Ringer**, **Plasma‚ÄëLyte**, **Hartmann**) have **lower chloride** and **more physiologic composition** than **0.9% saline**.
2. **0.9% saline** contains **154 mEq/L** each of **sodium** and **chloride** with **osmolarity 308 mOsm/L**.
3. **Albumin** solutions are **colloids** available as **iso‚Äëoncotic (5%)** and **hyper‚Äëoncotic (20‚Äì25%)** preparations.

---

<!--Selection of Vasopressors and Inotropes-->
<table>
  <caption><strong>Selection of Vasopressors and Inotropes</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Type of Shock</th>
      <th>Receptor Target</th>
      <th>Primary Effect</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Angiotensin II</td>
      <td>Distributive</td>
      <td>AT II</td>
      <td>‚Üë SVR</td>
      <td>Role still being defined</td>
    </tr>
    <tr>
      <td>Dobutamine (inotrope)</td>
      <td>Cardiogenic, Distributive</td>
      <td>Œ≤<sub>1</sub>, Œ≤<sub>2</sub></td>
      <td>‚Üë Inotropy</td>
      <td>First choice for cardiogenic shock without hypotension; may be added to norepinephrine for septic shock with depressed cardiac function</td>
    </tr>
    <tr>
      <td>Milrinone (inotrope)</td>
      <td>Cardiogenic</td>
      <td>PDE3 (inhibitor)</td>
      <td>‚Üë Inotropy</td>
      <td>Alternative agent in cardiogenic shock refractory to other agents</td>
    </tr>
    <tr>
      <td>Dopamine (high-dose)</td>
      <td>Cardiogenic</td>
      <td>D, Œ±<sub>1</sub>, Œ≤<sub>1</sub></td>
      <td>‚Üë SVR, ‚Üë Inotropy</td>
      <td>Associated with increased mortality compared with norepinephrine in distributive shock; use only in severe bradycardia in septic shock</td>
    </tr>
    <tr>
      <td>Dopamine (low-dose)</td>
      <td>Cardiogenic</td>
      <td>D, Œ≤<sub>1</sub></td>
      <td>‚Üë Inotropy, ‚Üë HR</td>
      <td>Not recommended to augment renal blood flow</td>
    </tr>
    <tr>
      <td>Epinephrine</td>
      <td>Cardiogenic, Distributive, Hypovolemic</td>
      <td>Œ±<sub>1</sub>, Œ±<sub>2</sub>, Œ≤<sub>1</sub>, Œ≤<sub>2</sub></td>
      <td>‚Üë SVR, ‚Üë Inotropy</td>
      <td>First choice for anaphylactic shock; may be added to norepinephrine and vasopressin in persistent septic shock; may be used as a single agent in septic shock with depressed cardiac function</td>
    </tr>
    <tr>
      <td>Norepinephrine</td>
      <td>Cardiogenic, Distributive, Hypovolemic</td>
      <td>Œ±<sub>1</sub>, Œ±<sub>2</sub>, Œ≤<sub>1</sub></td>
      <td>‚Üë SVR, ‚Üë Inotropy</td>
      <td>First choice in cardiogenic, distributive, and hypovolemic shock</td>
    </tr>
    <tr>
      <td>Phenylephrine</td>
      <td>Distributive</td>
      <td>Œ±<sub>1</sub></td>
      <td>‚Üë SVR</td>
      <td>Alternative agent in distributive shock when tachyarrhythmias preclude use of first-line agents</td>
    </tr>
    <tr>
      <td>Vasopressin</td>
      <td>Distributive, Hypovolemic</td>
      <td>V</td>
      <td>‚Üë SVR</td>
      <td>May be added to norepinephrine in persistent septic shock; no role in other shock states</td>
    </tr>
  </tbody>
</table>

<p><em>AT II = angiotensin type II; D = dopamine; HR = heart rate; PDE3 = phosphodiesterase 3; SVR = systemic vascular resistance; V = vasopressin.</em></p>

#### ‚úÖ True Statements (from Table: Selection of Vasopressors and Inotropes)
1. **Dobutamine** is the **first choice for cardiogenic shock without hypotension** and may be **added to norepinephrine** for **septic shock with depressed cardiac function**.  
2. **Milrinone** is an **alternative inotrope** for **cardiogenic shock refractory** to other agents.  
3. **High-dose dopamine** increases **mortality** compared with **norepinephrine** in distributive shock and should be reserved for **severe bradycardia in septic shock**.  
4. **Low-dose dopamine** is **not recommended** to augment **renal blood flow**.  
5. **Epinephrine** is the **first choice for anaphylactic shock** and may be **added to norepinephrine and vasopressin** in persistent septic shock; it can also be used alone in septic shock with depressed cardiac function.  
6. **Norepinephrine** is the **first-line vasopressor** for **cardiogenic, distributive, and hypovolemic shock**.  
7. **Phenylephrine** is an **alternative vasopressor** for **distributive shock** when **tachyarrhythmias** limit use of first-line agents.  
8. **Vasopressin** may be **added to norepinephrine** in **persistent septic shock**, but it has **no role in other shock states**.  
9. The role of **angiotensin II** in distributive shock is **still being defined**.